Literature DB >> 460304

Lack of evidence for cancer due to use of metronidazole.

C M Beard, K L Noller, W M O'Fallon, L T Kurland, M B Dockerty.   

Abstract

Experimental studies have shown that metronidazole is carcinogenic in rodents and mutagenic in bacteria. In 771 women given metronidazole for the treatment of vaginal trichomoniasis, more cancers developed than had been expected after exclusion of carcinoma of one uterine cervix (observed, 24 cases; expected on the basis of the Connecticut Tumor Registry, 21.7; expected on the basis of the Third National Cancer Survey, 18.4). However, the excess was not statistically significant (P greater than 0.05). The observed and expected numbers of breast-cancer cases were the same, but four lung-cancer cases were observed, whereas 0.6 would have been expected. This finding is confounded by the fact that all four lung cancers developed in women who were smokers. Overall, we observed no appreciable increase in cases of cancer.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 460304     DOI: 10.1056/NEJM197909063011003

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  24 in total

Review 1.  Antibiotics and breast-feeding: a critical review of the literature.

Authors:  Allison M Chung; Michael D Reed; Jeffrey L Blumer
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

2.  Amebiasis in the newborn.

Authors:  Ayla Güven
Journal:  Indian J Pediatr       Date:  2003-05       Impact factor: 1.967

3.  Anti-anaerobic antimicrobial agents: cefoxitin, cefotetan, clindamycin, and metronidazole.

Authors:  J A Bosso; R A Prince
Journal:  Tex Heart Inst J       Date:  1990

Review 4.  Antianaerobic antimicrobials: spectrum and susceptibility testing.

Authors:  Itzhak Brook; Hannah M Wexler; Ellie J C Goldstein
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

Review 5.  Clinical and microbiological aspects of Trichomonas vaginalis.

Authors:  D Petrin; K Delgaty; R Bhatt; G Garber
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

6.  Crohn's disease and leukemia.

Authors:  J A Girón; M Yebra; J J Solovera; L Abreu; J Diego; F Bonilla; A Durántez
Journal:  Dig Dis Sci       Date:  1985-04       Impact factor: 3.199

Review 7.  Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.

Authors:  S B Hanauer; G Stathopoulos
Journal:  Drug Saf       Date:  1991 May-Jun       Impact factor: 5.606

Review 8.  Clinical pharmacokinetics of metronidazole.

Authors:  E D Ralph
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

Review 9.  Effects of antibacterials on the unborn child: what is known and how should this influence prescribing.

Authors:  A Einarson; S Shuhaiber; G Koren
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 10.  Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.

Authors:  A H Lau; N P Lam; S C Piscitelli; L Wilkes; L H Danziger
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.